Lannett says it is satisfied with its reported sales of $144.4m for the third quarter of its financial year ending in June 2020, despite this representing a 16.4% drop compared to the $172.8m reported for the third quarter of fiscal 2019.
CEO Tim Crew explained that after losing the distribution deal for highly profitable thyroid drug levothyroxine – when former partner Jerome Stevens chose to switch its supply contract to Amneal in March 2019 – the reported third-quarter
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?